Team and Board

Leadership Team

hughes
Dr. Ken Hughes, Chief Executive Officer is a biomedical scientist, executive and entrepreneur with 20 years of experience in strategic and operational management in the biotechnology and biopharmaceutical industries. In his previous experience, Dr. Hughes was the Vice President, Scientific & Regulatory Affairs at the Industry Association for Canada‚ Research-Based Pharmaceutical Companies (RxandD); Industry Member of Clinical Trials Ontario; Co-founder and Scientific Advisory Board member of the biotechnology company PlantForm Corporation; and Vice President, Scientific Affairs at Microbix Biosystems Inc. He is also the founder and President of Roker Biotechnologies Inc., a company that provides consulting services to the Biotechnology and Biopharmaceutical industries, primarily focused on business environment, process development and regulatory strategy.

wrana

Dr. Jeff Wrana, Chief Scientific Officer is internationally recognized for his cancer research out of Mount Sinai Hospital’s Lunenfield-Tanenbaum Research Institute (LTRI). While most current cancer investigations focus on specific disease pathways, Dr. Wrana has shown that cancer involves a complex network of pathways that work together to misregulate cells and cause disease. Dr. Wrana’s research aims to expose the mechanisms involved in the development of these networks and to reveal new targets for treatments. He established the SMART high throughput biology centre and the Network Biology Collaboration Centre (with Dr. AC Gingras) at the LTRI. Dr. Wrana is the recipient of the following awards and recognitions: Queen Elizabeth II Diamond Jubilee Medal from the Prime Minister of Canada (2013); Ontario Premier’s Summit Award in Medical Research (2010); the Paul Marks Prize for Cancer Research, Memorial Sloan Kettering Cancer Center, NY, (2005); the Merck Frosst Prize Canadian Society of Biochemistry Molecular and Cell Biology (2002); Canadian Institute of Health Research, Investigator Award (2000-2005); Premier of Ontario’s Research Excellence Award (1999) and the Gertrude B. Elion Cancer Research Award from the American Association for Cancer Research (1997).

zlotta

Dr. Alexandre Zlotta, Chief Medical Officer is an internationally renowned uro-oncologic surgeon specializing in treating cancers of the bladder and prostate. Prior to being recruited to Mount Sinai Hospital from Brussels, Belgium in 2006, he earned the 2000 European Association of Urology Crystal Matula Award, which is given to the most promising European urologist under the age of 40. Today, Dr. Zlotta is Director of Uro-Oncology at Mount Sinai Hospital; Associate Member of Mount Sinai Hospital’s Lunenfield-Tanenbaum Research Institute (LTRI); leads the Bladder Cancer Research Program at The University Health Network and Mount Sinai Hospital and is a staff surgeon at Princess Margaret Cancer Centre – Toronto General Hospital/ University Health Network. He is also a Professor in the Department of Surgery (Urology) and a Director of the Uro-Oncology Fellowship Program at the University of Toronto. Dr. Zlotta is an Associate Editor for the Journal “Bladder Cancer”, Consulting Editor for European Urology, the leading urology journal world-wide and is on the editorial board of several other international journals. He is a board member of the North American “Society of Urologic Oncology” and of the Scientific Committee of Bladder Cancer Canada. He has been a board member on numerous Scientific Asociations including the National Cancer Institute of Canada – Prevention Initiative; the Scientific Committee of the European Association of Urology; the European Society of Oncological Urology; the Scientific Committee of the Belgian Association of Urology; and the Belgian National College of Oncology. He received in 2012 the Platinum Award of the European Association of Urology.

azad
Dr. Azar Azad, Chief Operating Officer, is also Managing Director of Mount Sinai Services Inc. (MSS), which is a major investor in iTP. Dr. Azad joined Mount Sinai in 2001, initially as co-Director of the Banting and Best Diabetes Center Core Laboratory, and her leadership has been instrumental in helping MSS grow and diversify. As MD at MSS, Dr. Azad has managed a wide range of projects and collaborations, providing strategic direction from both a scientific and business perspective. She is experienced in collaborating with both academic researchers and industry clients, and on customizing scientific and clinical solutions. Most recently, Azar led MSS in securing ISO 15189 certification‚ a first for a Canadian research lab. Dr. Azad has her Doctorate degree in Medical Laboratory Sciences, and her Ph.D. in Clinical Biochemistry. She performed her post-doctoral training at the University of Toronto and is a certified Lean Six Sigma Black Belt.

Board of Directors

Joseph Regan, MBA, Chair of the Board for ITP Biomedica has two decades of investment experience in innovative technologies and diverse business models and has served on the Board of Directors for over thirty companies. As a venture capitalist, Joe is experienced at vetting organizations to ensure they have what it takes to be successful. Strategic, analytical and focused on value creation, he has negotiated countless financial and strategic agreements in the biotechnology industry. Select transactions in the healthcare sector include Cytochroma Inc. (Mitsubishi Tanabe Pharmaceutical Company global alliance, subsequently acquired by OPKO Health, Inc.), Ambit Biosciences Corporation (IPO – NASDAQ: AMBI; subsequent acquisition by Daiichi Sankyo), and GeminX Pharmaceuticals Inc. (acquired by Cephalon Inc., now owned by Teva Pharmaceuticals, Inc.). Joe has an Honours BSc (with distinction) from the University of Guelph and an MBA (Dean’s List) from McMaster University.
stephen goldsmith
Stephen Goldsmith, MBA – Stephen’s career story illustrates the adaptability and drive that is necessary to see any start-up organization through to success. He is currently Vice President, Business Development at the Sinai Health System, leading all revenue-generating businesses at Mount Sinai Hospital, Bridgepoint Health, and Circle of Care. Mount Sinai Hospital is an internationally recognized 442-bed acute care academic health sciences centre affiliated with the University of Toronto that specializes in cancer care and chronic disease management, amongst other mandates. Prior to this position, Stephen was head of business development for Mount Sinai Hospital’s Fertility Clinic. Previous to working in healthcare, Stephen drove global brands in several capacities: first at Proctor & Gamble; next at the internet consulting firm, Cyberplex, where he worked with clients such as Sony, Chrysler, and Sprint; and then as an independent sports and celebrity marketing agent where he represented Magic Johnson, Pedro Martinez and Pamela Anderson amongst others. Stephen has an undergraduate degree in Administrative and Commercial Studies from the University of Western Ontario and an MBA from Queen’s University.

Ken Hughes, Chief Executive Officer – see profile above
Jeff Wrana, Chief Scientific Officer – see profile above
Contact iTP: Ken Hughes - hughes@itpbiomedica.com - (416) 702-1187